Showing results (81-90 of 88) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Alzheimer'S & Dementia (New York, N. Y.)|November 11, 2017
Characterization of APOE and TOMM40 allele frequencies in the Japanese populationAkira Nishimura, Hidenori Nonomura, Shingo Tanaka, et al.The Spine Journal : Official Journal of the North American Spine Society|July 13, 2014
The impact of preoperative depression on quality of life outcomes after posterior cervical fusionMatthew D Alvin, Jacob A Miller, Swetha Sundar, et al.Alzheimer'S & Dementia (New York, N. Y.)|October 12, 2020
Advancing combination therapy for Alzheimer's diseaseStephen P Salloway, Jeff Sevingy, Kumar Budur, et al.Journal of Neurodevelopmental Disorders|November 19, 2025
Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension studyElizabeth Berry-Kravis, Randi Hagerman, Jonathan Cohen, et al.Alzheimer'S & Dementia (New York, N. Y.)|August 11, 2018
TOMMORROW neuropsychological battery: German language validation and normative studyHeather R Romero, Andreas U Monsch, Kathleen M Hayden, et al.The Lancet. Neurology|November 19, 2022
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialMichael J Soileau, Jason Aldred, Kumar Budur, et al.Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
Measuring cognition and function in the preclinical stage of Alzheimer's diseaseSandra Weintraub, Maria C Carrillo, Sarah Tomaszewski Farias, et al.Neurology and Therapy|August 26, 2023
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.Pageof 9